Compare AU

Compare CURE vs. INCM

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Global Income Leaders ETF (INCM). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

INCM

Popularity

Low

Low

Pearlers invested

83

13

Median incremental investment

$619.50

$1,240.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$4,773.60

Average age group

> 35

> 35


Key Summary

CURE

INCM

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

INCM.AX was created on 2018-10-18 by BetaShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The fund aims to track the performance of an index (before fees and expenses) that comprises 100 high-yielding global companies (ex-Australia) selected for their potential to generate attractive and sustainable income.

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

ALTRIA GROUP INC (3.34 %)

AT&T INC (2.08 %)

VERIZON COMMUNICATIONS INC (1.92 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Other (30.45 %)

Utilities (24.29 %)

Consumer Staples (11.82 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

United States (70.82 %)

Korea (4.54 %)

Hong Kong (3.66 %)

Management fee

0.45 %

0.45 %


Key Summary

CURE

INCM

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

Nasdaq Global Income Leaders Index - USD-US Dollar

Asset class

ETF

ETF

Management fee

0.45 %

0.45 %

Price

$51.33

$18.72

Size

$36.301 million

$35.332 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

4.13 %

Market

ASX

ASX

First listed date

12/11/2018

22/10/2018

Purchase fee

$6.50

$6.50


Community Stats

CURE

INCM

Popularity

Low

Low

Pearlers invested

83

13

Median incremental investment

$619.50

$1,240.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$4,773.60

Average age group

> 35

> 35


Pros and Cons

CURE

INCM

Pros

  • Higher exposure to US market

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Lower distribution yield

CURE

INCM

Higher exposure to US market

Lower exposure to US market

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home